NEWS
Blueprint for AI in UK healthcare
The National Commission into the Regulation of AI in Healthcare has published its recommendations on how the UK can strengthen the regulation of AI in healthcare, so it remains safe, keeps pace with innovation, and continues to earn people’s trust. The report Recommendations
for a future regulatory framework, contains new recommendations based on extensive public engagement set out how the NHS could give patients faster access to AI advances with proportionate safeguards to protect patient safety and maintain high levels of trust. The Commission was established
by the MHRA in September 2025 as an independent, non-statutory advisory body to support the safe, fast and trusted regulation, development and use of AI in healthcare, in line with commitments in the 10-Year Health Plan for England and the Life Sciences Sector Plan. The Commission gathered evidence
from more than 12,000 people over the course of a year, including patients, the public, clinicians, healthcare leaders, industry and technology developers, making it the largest engagement of its kind ever undertaken in the UK on the regulation of healthcare technology. Additional in-depth deliberative research by research partner the Health Foundation with members of the UK public, published today, provided detailed insight into the UK public’s priorities and expectations for the regulation of AI in healthcare. Taken together, that engagement found broad public support for AI in healthcare, with clear conditions: strong safety standards, meaningful human oversight, and transparency about when and how AI is being used in someone’s care. The Commission’s recommendations respond directly to these views. Recommendations include: Faster access to safe and effective AI Continuous, real-world monitoring throughout a device’s lifecycle Public access to safety information Tougher powers to protect patients.
The government and the MHRA will now carefully consider the Commission’s recommendations, with a formal response to follow in due course.
10
WWW.PATHOLOGYINPRACTICE.COM October 2026
Cruinn enters UK with Katalyst acquisition
Irish laboratory supplier Cruinn Diagnostics has announced the acquisition of Katalyst Diagnostics, a UK-based point- of-care diagnostics business serving NHS and clinical customers across mental health, oncology, paediatrics and other specialist care setings. The acquisition bolsters Cruinn’s
footprint in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates new opportunities to introduce Cruinn products to UK customers, while leveraging Cruinn’s established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. The combined group now has more
than 100 employees and revenues above €50 million. Over the coming years, Cruinn has ambitious growth plans both organically and through further acquisitions in the UK and Ireland. Katalyst’s point-of-care diagnostics
portfolio complements Cruinn’s established strength in laboratory diagnostics. The business will continue to focus on the UK market, where Cruinn
sees significant opportunity to expand its market through further investment and targeted mergers and acquisitions. Peter Hussey, CEO at Cruinn
Diagnostics (pictured), said: “Katalyst Diagnostics is a strong strategic fit for Cruinn and gives us a solid platform in the UK market from day one. The business brings established NHS customer relationships, local market knowledge and a differentiated point-of-care diagnostics portfolio that complements our existing capabilities. Together, we see a clear opportunity to support customers across Ireland and the UK with a broader range of diagnostic solutions, while building a larger and more diversified group.” Katalyst will continue to operate under its existing leadership, with Afsheen Khan remaining as Managing Director.
Unilabs expanding digital pathology operations with Proscia
Proscia has announced that Unilabs, one of the leading providers of medical diagnostic services in Europe, is leveraging the Concentriq platform to support the advancement of digital pathology across its network. Multiple Unilabs countries are already using Concentriq AP-Dx for routine case review, with others expected to deploy it before the end of the year. Unilabs’ pathology network includes more than 350 experts and 400 laboratory
technicians across 12 countries and analyses nine million sections each year. Concentriq brings together these teams, laboratory sites, diagnostic data, and AI capabilities in a single enterprise environment. Rather than confining expertise to an individual location, Concentriq gives hospitals and healthcare institutions easy access to the broader Unilabs network. With Proscia, Unilabs is also shaping pathology’s growing role in precision medicine. Concentriq gives Unilabs’ pathologists easy access to their AI applications through seamless interoperability. As pathology AI continues to shift toward advanced tests, including image-based companion diagnostics, Unilabs can draw on its digital foundation and Proscia’s expertise to incorporate these approaches into practice.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
